TCRX arrives at tomorrow's Q1 2026 results having shed more than half its short interest in a month — a sharp retreat that stands out for a micro-cap biotech carrying this much clinical risk.
The short-selling pullback is the defining feature of the current setup. Estimated short interest collapsed roughly 51% over the past 30 days to around 940,000 shares, after running near 1.9 million through most of April. The borrow market tells the same story: cost to borrow has eased to just 0.62% APR, roughly half of where it was a month ago, and availability remains wide open. That combination — fewer shorts, cheap borrow, loose availability — points to a lending market with almost no squeeze pressure heading into the print.
The stock has responded to that retreat with momentum. It's up 24% over the past month and 9% on the week to close at $1.25, outpacing most of its small-cap biotech peers. Correlated names like ACET and SANA also gained 12% on the week, so some of the move reflects a broader sector bid — but TCRX's one-month run is considerably sharper. The ORTEX short score sits at a relatively modest 31, well below the levels seen in late April when it briefly spiked toward 36, confirming that short-side pressure has genuinely eased rather than simply paused.
The analyst picture is mixed, and the most recent data worth citing dates from early March. Wedbush maintained its Outperform rating and lifted its target to $5 from $4 after the last earnings print — a constructive signal, but from a stock then trading near similar levels to today. Earlier analyst moves, including target cuts to $6-$7 by HC Wainwright and Needham following last November's results, reflect the damage done by TSC-101's 18% relapse rate data and the subsequent workforce reduction. The consensus is effectively a single Hold rating, which understates the bull-bear divide: the bull case rests on the Amgen collaboration revenue ($2.5 million quarterly) providing a partial cash bridge and the pivot toward hematologic malignancies giving TSC-101 a cleaner clinical path. Bears point to the 30% workforce cut, the paused solid-tumor enrollment, and a cash runway that the company itself characterizes as extending only into late 2027. Enterprise value sits just above $100 million against an estimated net loss of around $106 million, so valuation provides no obvious floor. The price-to-book ratio has risen 17% over the past month as the stock recovered, now at roughly 1.0x — a level that prices in almost no incremental clinical progress.
Past earnings prints have been volatile in both directions. The November 2025 report sent the stock down 10% on the day and nearly 10% over the following week. The March 2026 update reversed that, gaining 9% on the day and extending to 11% over five days. Tomorrow's report will test whether the cash position, enrollment update for the hematologic study, and any signal on future Amgen collaboration terms are enough to sustain a run that has already priced in considerable optimism.
See the live data behind this article on ORTEX.
Open TCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
